Unmet Need and Clinical Significance in Treatment-Naive Patients

Follicular lymphoma (FL) is an indolent, slow-progressing cancer, and a 'watch and wait' strategy is standard practice in the early stages, rather than immediate treatment. However, predicting which patients will rapidly progress and require treatment has been challenging with conventional imaging and blood tests. This prospective clinical study (NCT03190928), led by the National Cancer Institute (NCI), was designed to track circulating tumor DNA (ctDNA) in patients' blood to elucidate the disease's progression at the molecular level. This provides a scientific basis for determining the optimal timing for precision therapy tailored to individual patients' clonal evolution, while minimizing unnecessary treatment side effects.

Technical Achievements and Data Validation of the clonoSEQ Platform

In this study, Adaptive Biotechnologies' (ADPT) next-generation sequencing (NGS)-based minimal residual disease (MRD) assessment platform, clonoSEQ, was used as a key analytical tool. Researchers conducted detailed analyses on 78 treatment-naive patients enrolled from July 2017 to August 2021. The results demonstrated the overwhelming sensitivity of liquid biopsy technology, identifying unique tumor clonotypes in 100% of patients with available tissue biopsy samples and 37% of patients without. Plasma ctDNA levels showed a high correlation with the Follicular Lymphoma International Prognostic Index (FLIPI) score and lactate dehydrogenase (LDH) levels, both established high-risk prognostic indicators, confirming its reliability as a diagnostic tool.

Statistical Differentiation in Predicting Tumor Regression and Malignant Transformation

According to the analysis presented at the 2024 American Society of Hematology (ASH) meeting, baseline ctDNA levels in patients before treatment were statistically confirmed as a strong predictor of tumor behavior. In particular, the spontaneous regression of tumors was significantly more observed in the patient group with initially low ctDNA levels (p=0.02). In contrast, no statistical association was observed between baseline ctDNA levels and histologic transformation (HT), the progression to a more aggressive form of the disease (p=0.85). These findings suggest that tumor growth and malignant transformation into different genetic pathways, highlighting the need for differentiated monitoring approaches in future treatment planning.

Impact on the Diagnostics and Drug Development Markets

The global follicular lymphoma treatment and diagnostics market is a large and growing market, estimated at up to $5.93 billion by 2026, and the trend is shifting towards targeted therapies that exclude chemotherapy, such as epcoritamab. This clinical trial provides important clinical evidence that Adaptive Biotechnologies (ADPT) can expand the indications for clonoSEQ from existing blood cancer monitoring to predicting the optimal timing for initial treatment in follicular lymphoma. In the medium to long term, it is expected to reduce the number of costly CT or PET scans, minimizing patients' radiation exposure and reducing healthcare costs. Furthermore, it is expected to encourage multinational pharmaceutical companies to actively adopt ctDNA as a standard endpoint for monitoring treatment response in new drug clinical trials.